Cubist Pharmaceuticals ( Cubist Pharmaceuticals)

Primary tabs

Cubist Pharmaceuticals's picture

Management

Contact Address

About Cubist Pharmaceuticals

Cubist Pharmaceuticals was a U.S. biopharmaceutical company with activities spanning from research and development to commercialization of pharmaceutical products. Its main products target pathogens like MRSA.

Cubist Pharmaceuticals press release, blog etc

Wed, 01/30/2019 - 06:55 Merck Receives Breakthrough Therapy Designation from FDA for V114, the Companys Investigational 15-Valent Conjugate Vaccine for the Prevention of Invasive Pneumococcal Disease, in Infants, Children, and Adolescents
Thu, 12/20/2018 - 03:42 LYNPARZA (olaparib) Meets Primary Endpoint in Phase 3 SOLO-3 Trial for the Treatment of Relapsed BRCA-Mutated Advanced Ovarian Cancer
Wed, 12/19/2018 - 04:35 LYNPARZA (olaparib) Approved by FDA for First-Line Maintenance Therapy in BRCA-Mutated Advanced Ovarian Cancer
Mon, 12/10/2018 - 01:21 Mercks President of Global Human Health Adam H. Schechter to Leave Merck Frank Clyburn Named Chief Commercial Officer and Michael Nally Named Chief Marketing Officer
Sun, 06/30/2013 - 10:12 Cubist Pharmaceuticals Reports Second Quarter 2013 Financial Results
Sun, 03/31/2013 - 13:05 Cubist Pharmaceuticals Reports First Quarter 2013 Financial Results
Mon, 06/29/2009 - 10:56 Phase 1 Trial Begins for Investigational New Drug for MDR Gram-negative Infections -- Second Phase 1 trial to emerge from Cubist
Mon, 06/29/2009 - 10:52 Cubist 1Q09 Total Net Revenues Up 37%
Mon, 06/29/2009 - 10:50 Cubist Pharmaceuticals Initiates Phase 2 Trial for Therapy to Reduce Blood Loss During Surgery
Mon, 06/29/2009 - 10:50 Cubist Pharmaceuticals Ranks No. 1 in The Boston Globe's Annual Globe 100 List of Best Performing Companies
Mon, 06/29/2009 - 10:48 Cubist Pharmaceuticals Files Patent Infringement Lawsuit Against Teva Parenteral Medicines, Inc.

InfoBox

HomePagewww.cubist.com
Wikipediaen.wikipedia.org/wiki/Cubist_Pharmaceuticals